Baxter Nov. 26 announced new allocation levels for multiple IV product groups and advised customers of a one- to two-week lead time for products to flow through its supply and distribution network. Allocation and fulfillment levels may vary based on product availability at the time of the order. In a letter shared with customers, Baxter highlighted increased allocations for 0.9% sodium chloride product groups. Its 1000 ml group will increase from 60% to 80%, its 500 ml group from 60% to 90% and its 250 ml group from 60% to 90%. The company said it expects to share details later this month on the next phase of increased allocations and expects to reach 100% allocation across several IV product codes by the end of the month.

Related News Articles

Headline
Supplies of Mo-99/Tc-99M, which are medical radioisotopes used in procedures to diagnose and detect diseases including heart disease and cancer, are…
Headline
Baxter announced Oct. 31 that it has restarted its North Cove, N.C. facility's highest-throughput IV solutions manufacturing line, which normally accounts for…
Headline
The AHA Oct. 28 issued a Special Bulletin to members informing them of the Food and Drug Administration's authorization extending the use date for certain…
Headline
The Centers for Disease Control and Prevention has issued a health advisory on the supply disruption of peritoneal dialysis and intravenous solutions due to…
Headline
Baxter announced that it is increasing the current U.S. allocation levels of its highest-demand IV fluids for direct customers from 40% to 60%, and for…
Headline
The Centers for Disease Control and Prevention has issued an advisory alerting health care providers, laboratory professionals and others in health care…